JP2019506403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506403A5 JP2019506403A5 JP2018538596A JP2018538596A JP2019506403A5 JP 2019506403 A5 JP2019506403 A5 JP 2019506403A5 JP 2018538596 A JP2018538596 A JP 2018538596A JP 2018538596 A JP2018538596 A JP 2018538596A JP 2019506403 A5 JP2019506403 A5 JP 2019506403A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 122
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 54
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 37
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 37
- 239000000556 agonist Substances 0.000 claims 35
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662286616P | 2016-01-25 | 2016-01-25 | |
| US62/286,616 | 2016-01-25 | ||
| PCT/IB2017/050244 WO2017130076A1 (en) | 2016-01-25 | 2017-01-17 | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506403A JP2019506403A (ja) | 2019-03-07 |
| JP2019506403A5 true JP2019506403A5 (enExample) | 2019-10-24 |
| JP6783312B2 JP6783312B2 (ja) | 2020-11-11 |
Family
ID=57956335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538596A Expired - Fee Related JP6783312B2 (ja) | 2016-01-25 | 2017-01-17 | がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190031765A1 (enExample) |
| EP (1) | EP3408294A1 (enExample) |
| JP (1) | JP6783312B2 (enExample) |
| KR (2) | KR20210013777A (enExample) |
| CN (1) | CN108473587A (enExample) |
| AU (2) | AU2017211540B2 (enExample) |
| BR (1) | BR112018014016A2 (enExample) |
| CA (1) | CA2955184A1 (enExample) |
| HK (1) | HK1259253A1 (enExample) |
| MX (1) | MX2018008995A (enExample) |
| RU (1) | RU2748949C2 (enExample) |
| WO (1) | WO2017130076A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| WO2018191502A2 (en) | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
| US20200129637A1 (en) | 2017-04-20 | 2020-04-30 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| EP3638373B1 (en) | 2017-06-14 | 2024-09-04 | ADC Therapeutics SA | Dosage regimes for the administration of an anti-cd19 adc |
| SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019178852A1 (zh) * | 2018-03-23 | 2019-09-26 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| WO2019196868A1 (en) | 2018-04-10 | 2019-10-17 | Wuxi Biologics (Shanghai) Co., Ltd. | A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof |
| CN110357961B (zh) * | 2018-04-10 | 2022-08-23 | 无锡智康弘义生物科技有限公司 | 抗人4-1bb单克隆抗体及其制备方法和用途 |
| EP3796942A1 (en) | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molecular adjuvant |
| EP3826626A4 (en) | 2018-07-23 | 2022-07-06 | Magenta Therapeutics, Inc. | USE OF ANTI-CD137 ANTIBODY-DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| EP3976043A1 (en) * | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| WO2021059136A1 (en) | 2019-09-25 | 2021-04-01 | Pfizer Inc. | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| WO2021141977A1 (en) | 2020-01-07 | 2021-07-15 | Board Of Regents, The University Of Texas System | Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy |
| JP2023513006A (ja) | 2020-01-29 | 2023-03-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用 |
| EP4096789A4 (en) | 2020-01-29 | 2023-10-11 | Board of Regents, The University of Texas System | USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS |
| PE20230784A1 (es) | 2020-05-19 | 2023-05-11 | Boehringer Ingelheim Int | Moleculas de fijacion para el tratamiento de cancer |
| JP2023531042A (ja) * | 2020-06-30 | 2023-07-20 | 諾納生物（蘇州）有限公司 | ４－１ｂｂ結合タンパク質及びその用途 |
| CN114515335A (zh) * | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| WO2022250502A1 (en) * | 2021-05-27 | 2022-12-01 | Yuhan Corporation | Ox40 agonist and use thereof |
| WO2023036041A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗4-1bb的激动型抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP4741074B2 (ja) | 1998-02-24 | 2011-08-03 | シスターズ オブ プロビデンス イン オレゴン | Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法 |
| AU764211C (en) | 1998-12-01 | 2006-03-30 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| CA2588157A1 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| CA2610661A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| KR20150061041A (ko) * | 2007-12-14 | 2015-06-03 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ｏｘ４０ 수용체에 대한 결합 분자 |
| SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
| EP2726275B1 (en) | 2011-06-30 | 2019-12-04 | Compagnie Générale des Etablissements Michelin | Method and apparatus for installing a tread ring upon a tire carcass |
| WO2013119202A1 (en) | 2012-02-06 | 2013-08-15 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using ox40 agonists |
| AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| US10023649B2 (en) * | 2014-05-21 | 2018-07-17 | Pfizer Inc. | Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist |
| WO2016205277A1 (en) * | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
-
2017
- 2017-01-17 WO PCT/IB2017/050244 patent/WO2017130076A1/en not_active Ceased
- 2017-01-17 JP JP2018538596A patent/JP6783312B2/ja not_active Expired - Fee Related
- 2017-01-17 CN CN201780007730.6A patent/CN108473587A/zh active Pending
- 2017-01-17 EP EP17702687.9A patent/EP3408294A1/en not_active Withdrawn
- 2017-01-17 MX MX2018008995A patent/MX2018008995A/es unknown
- 2017-01-17 CA CA2955184A patent/CA2955184A1/en active Pending
- 2017-01-17 US US16/069,712 patent/US20190031765A1/en not_active Abandoned
- 2017-01-17 KR KR1020217002980A patent/KR20210013777A/ko not_active Ceased
- 2017-01-17 KR KR1020187024267A patent/KR20180103150A/ko not_active Ceased
- 2017-01-17 HK HK19101614.3A patent/HK1259253A1/zh unknown
- 2017-01-17 BR BR112018014016A patent/BR112018014016A2/pt not_active IP Right Cessation
- 2017-01-17 RU RU2018127164A patent/RU2748949C2/ru active
- 2017-01-17 AU AU2017211540A patent/AU2017211540B2/en not_active Ceased
-
2020
- 2020-07-27 AU AU2020210145A patent/AU2020210145A1/en not_active Abandoned